Chongqing Lummy Pharmaceutical Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Rongzhao Qiu

Chief Executive Officer (CEO)

CN¥830.8k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.4yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Rongzhao Qiu (30 yo)

4.4yrs

Permanencia

CN¥830,800

Compensación

Mr. Rongzhao Qiu is General Manager of Chongqing Lummy Pharmaceutical Co., Ltd. from June 12, 2020.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rongzhao Qiu	General Manager	4.4yrs	CN¥830.80k	sin datos
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.7yrs	CN¥867.50k	sin datos
Wen Lai	Financial Director	8.7yrs	CN¥678.40k	sin datos
Song Lin	Deputy GM & Director	1.9yrs	CN¥410.20k	sin datos
Dan Cui	Deputy GM	6.7yrs	CN¥359.70k	0.0016% CN¥ 81.9k

5.5yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300006 es experimentado (5.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.7yrs	CN¥867.50k	sin datos
Song Lin	Deputy GM & Director	1.8yrs	CN¥410.20k	sin datos
Yuan Yuan	Chairman of Supervisory Board	7.8yrs	sin datos	sin datos
Xujiang Chen	Independent Director	4.4yrs	CN¥88.50k	sin datos
Geng Chen	Independent Director	4.4yrs	CN¥88.50k	sin datos
Jiansheng Liang	Chairman	2.9yrs	CN¥729.40k	sin datos
Rihua Ou	Director	4.4yrs	sin datos	sin datos
Weiyan Tang	Director	4.4yrs	sin datos	sin datos
Changbi Li	Independent Director	4.4yrs	CN¥88.50k	sin datos
Huichuan Xu	Employee Supervisor	10.8yrs	sin datos	sin datos
Mingyue Tan	Supervisor	2.9yrs	sin datos	sin datos
Hai Run Wang	Director	1.8yrs	sin datos	sin datos

4.4yrs

Permanencia media

47yo

Promedio de edad

Junta con experiencia: La junta directiva de 300006 se considera experimentada (4.4 años de antigüedad promedio).

Chongqing Lummy Pharmaceutical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Less than half of directors are independent

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0 in 3Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 23, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.048 loss in 2Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.065 loss in FY 2022)

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.021 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.065 loss per share (vs CN¥0.10 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.021 loss per share (vs CN¥0.017 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.025 loss per share (vs CN¥0.055 profit in 1Q 2021)

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Full year 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.40 loss in FY 2020)

First quarter 2021 earnings released: EPS CN¥0.055 (vs CN¥0.01 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.40 loss per share (vs CN¥0.19 loss in FY 2019)

Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 200 million.

New 90-day low: CN¥6.65

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

Hangzhou Bulaisen Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Sichuan Hezheng Pharmaceutical Co., Ltd. from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 170 million.

New 90-day low: CN¥7.08

New 90-day high: CN¥8.54

New 90-day high: CN¥8.21

Third quarter earnings released

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad